Full Press Release Details
Investor and Media Contact:
Director, Communications
Targeted Genetics Corporation
TARGETED GENETICS ANNOUNCES TODD E. SIMPSON
TO STEP DOWN AS CHIEF FINANCIAL OFFICER
David Poston to be named as Acting CFO
Seattle, WA August 22, 2005 Targeted Genetics Corporation (Nasdaq: TGEN) announced today that
Todd E. Simpson, its Vice President, Finance and Administration, Chief Financial Officer, Treasurer
and Secretary will leave October 3, 2005 to accept a position with another company.
David Poston, Targeted Genetics Senior Director of Finance and Assistant Corporate Secretary, will
serve as acting Chief Financial Officer for the company upon Mr. Simpson s departure. David joined
the company in January 1999 and currently leads its finance and accounting operations including
internal and SEC financial reporting and financial controls, internal controls, budgeting, treasury
and all financial aspects of corporate collaborations. David has over twenty years of financial
experience, has had primary responsibility for public company financial disclosure matters since
1993 and started his career in public accounting at KPMG in 1985.
While we wish Todd well in his endeavors, we are pleased that David will be assuming the role of
Acting CFO. David s extensive experience and tenure at the company managing our financial
resources make him a natural choice as Acting CFO to facilitate a smooth transition, said H.
Stewart Parker, President and Chief Executive Officer.
About Targeted Genetics
Targeted Genetics Corporation is a biotechnology company committed to the development and
commercialization of innovative targeted molecular therapies for the prevention and treatment of
inflammatory arthritis and other acquired and inherited diseases with significant unmet medical
need. We use our considerable knowledge and capabilities in the development and manufacturing of
gene delivery technologies to advance a diverse product development pipeline. Our product
development efforts target inflammatory arthritis, AIDS prophylaxis,
congestive heart failure, Huntington s disease, and hyperlipidemia. To learn more about Targeted
Genetics, visit our website at www.targetedgenetics.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements regarding our business strategy, our product
development, our personnel and other statements about our plans, objectives, intentions and
expectations. In particular, the statements regarding the Company s future plans are
forward-looking statements. These statements, involve current expectations, forecasts of future
events and other statements that are not historical facts. Inaccurate assumptions and known and
unknown risks and uncertainties can affect the accuracy of forward-looking statements. Factors that
could affect our actual results include, but are not limited to, the timing, nature and results of
our clinical trials, potential development of alternative technologies or more effective products
by competitors, our ability to obtain and maintain regulatory or institutional approvals, our
ability to obtain, maintain and protect our intellectual property and our ability to raise capital
when needed, as well as other risk factors described in the section entitled Factors Affecting Our
Operating Results, Our Business and Our Stock Price in our Quarterly Report on Form 10-Q for the
period ended June 30, 2005. You should not rely unduly on these forward-looking statements, which
apply only as of the date of this release. We undertake no duty to publicly announce or report
revisions to these statements as new information becomes available that may change our